Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.Julia Quidde, Alexander Stein, Thomas Goehler et al.|Journal of Clinical Oncology|2017Cited by 2
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 1
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
PharmaNewsDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
Editorial Board / Contents / ImprintDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0